Nintedanib Slows Decline in RA-Associated Interstitial Lung Disease

(MedPage Today) -- Patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) had slower rates of decline in lung function over 1 year when treated with nintedanib (Ofev), an intracellular inhibitor of tyrosine kinases, according...